{"url_path":"/sec/ktta/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1841330/0001213900-26-057837-index.html","accession_number":"0001213900-26-057837","cik":"0001841330","ticker":"KTTA","issuer_name":"Pasithea Therapeutics Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1841330/0001213900-26-057837-index.html","primary_entity_key":"0001841330","primary_entity_name":"Pasithea Therapeutics Corp."},"word_count":331,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\n  \n\nExhibit No.\n \nDescription\n\n3.1\n \n[Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Pasithea Therapeutics Corp., as amended, dated January 28, 2026 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on January 28, 2026).](https://www.sec.gov/Archives/edgar/data/1841330/000121390026008828/ea027424401ex3-1_pasithea.htm)\n\n10.1\n \n[Second Amendment to Pasithea Therapeutics Corp. 2023 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on January 28, 2026).](https://www.sec.gov/Archives/edgar/data/1841330/000121390026008828/ea027424401ex10-1_pasithea.htm)\n\n10.2\n \n[Executive Employment Agreement, dated April 3, 2026, by and between Pasithea Therapeutics Corp. and Kartik Krishnan, M.D., Ph.D. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on May 4, 2026).](https://www.sec.gov/Archives/edgar/data/1841330/000121390026051681/ea028886401ex10-1.htm)\n\n31.1*\n \n[Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ea028915701ex31-1.htm)\n\n31.2*\n \n[Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ea028915701ex31-2.htm)\n\n32.1**\n \n[Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ea028915701ex32-1.htm)\n\n32.2**\n \n[Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ea028915701ex32-2.htm)\n\n101.INS*\n \nInline XBRL Instance Document.\n\n101.SCH*\n \nInline XBRL Taxonomy Extension Schema Document\n\n101.CAL*\n \nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n101.LAB*\n \nInline XBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE*\n \nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n101.DEF*\n \nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n104\n \nCover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)\n\n \n\n*\nFiled herewith.\n\n \n\n**\nFurnished, not filed.\n\n \n\n31\n\n \n\nSIGNATURES\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto\nduly authorized.\n\n \n\nPASITHEA THERAPEUTICS CORP.\n \n\n \n \n\nBy: \n*/s/ Tiago Reis Marques*\n \n\n \nTiago Reis Marques\n \n\n \nChief Executive Officer\n \n\n \n(Principal Executive Officer)\n \n\n \n \n\n \nDate: May 15, 2026\n \n\n \n\nBy: \n*/s/ Daniel Schneiderman*\n \n\n \nDaniel Schneiderman\n \n\n \nChief Financial Officer\n \n\n \n(Principal Financial Officer and\n\nPrincipal Accounting Officer)\n \n\n \n \n\n \nDate: May 15, 2026\n \n\n \n\n32"}